Mimedx (MDXG) Current Deferred Revenue (2011 - 2012)

Mimedx's (MDXG) quarterly Current Deferred Revenue came in at $6620.0 in Q1 2012, little changed quarter-over-quarter from $6620.0 in Q4 2011.

Mimedx (MDXG) Current Deferred Revenue (2011 - 2012) Analysis & Trends

Mimedx has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $6620.0 for Q1 2012.

Current Deferred Revenue for Q1 2012 came in at $6620.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2012 was $6620.0 (changed N/A YoY), and the FY2011 annual result was $6620.0, changed N/A from the prior year.
Current Deferred Revenue came in at $6620.0 for Q1 2012 at Mimedx, roughly flat from $6620.0 in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $6620.0 in Q2 2011 to a low of $6620.0 in Q2 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Mimedx	546.28 Mn	386.51 Mn	41.62 Mn

Download Data